A decade of improvement in Chronic Lymphocytic... - CLL Support
A decade of improvement in Chronic Lymphocytic Leukemia treatments means a shorter life expectancy is no longer a given
You need to be a member of this community to see this post.
12 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
10 Years in CLL: Top Advances From 2012-2022
For some of you, this is the story you witnessed.
For some of us, this is the near or more distant...
A New Era is Coming up in the Treatment of Chronic Lymphocytic Leukemia
This is an interesting overview from Italy
The survival of patients with chronic lymphocytic...
EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor
https://cllsociety.org/2022/08/eha-2022-outcomes-following-treatment-with-a-covalent-btk-and-bcl2-in
EHA 2019: Dr. Maloney on CAR-T and Dr. Davids of Chemo-Immunotherapy combinations
David Maloney is world expert in CAR-T therapy and was one of my doctors when I got my genetically...
Alterations of the immune system caused by CLL B‐cells
Abstract: Here, we review the current understanding of the underlying interplay between the...
Related Posts
New drug: MS-553 inhibitor for CLL/SLL who develop resistance to BTK inhibitors
Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects
Ibrutinib Slow but steady foreward movement.
Novel Bruton’s Tyrosine Kinase (BTK) inhibitor, ONO-4059 enters UK CLL clinical trial 
A new kid on the block? Nemtabrutinib
